Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Achieve Life Sciences  / Equity Bottom-Up

<ul><li>Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world.</li><li>Pivotal studies have been completed with safety & efficacy results exceeding expectations.</li><li>Achieve is now awaiting its target action date of June 20th 2026 and preparing for commercialization.</li></ul>

Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world.Pivotal studies have been completed with safety & efficacy results exceeding expectations.Achieve is now awaiting its target action date of June 20th 2026 and preparing for commercialization.

ACHV: Preparations Continue as PDUFA Date Assigned

<ul><li>Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world.</li><li>Topline results from ORCA-2 were reported in April 2022 and for ORCA-3 in May 2023.</li><li>Results exceeded expectations on safety & efficacy parameters.</li></ul>

Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world.Topline results from ORCA-2 were reported in April 2022 and for ORCA-3 in May 2023.Results exceeded expectations on safety & efficacy parameters.

ACHV: Kicking Butts to Achieve June NDA Filing

United States

Achieve Life Sciences, Inc. operates as a pharmaceutical company. The Company develops and commercializes cytisine treatment to help people battling nicotine addiction. Achieve Life Sciences serves customers in North America.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Achieve Life Sciences (ACHV US)

ACHV: FDA's CNPV Awarded for Vaping

Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world. Pivotal studies...

Zacks Small Cap Research

ACHV: Preparations Continue as PDUFA Date Assigned

Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world. Pivotal studies...

Zacks Small Cap Research

ACHV: Second Quarter Results

Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world. Topline results...

Zacks Small Cap Research

ACHV: Achieve's Busy Day

Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world. Topline results...

Zacks Small Cap Research

ACHV: Kicking Butts to Achieve June NDA Filing

Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world. Topline results...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)